title: Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
authors.forename: Maciej
authors.initials: M
authors.lastname: Machaczka
authors.forename: Johan
authors.initials: J
authors.lastname: Vaktnäs
authors.forename: Samuel C C
authors.initials: SC
authors.lastname: Chiang
authors.forename: Yenan T
authors.initials: YT
authors.lastname: Bryceson
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D033581:Stem Cell Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab